Comparative effectiveness for oral anti-diabetic treatments among newly diagnosed type 2 diabetics: data-driven predictive analytics in healthcare

Health Systems

Volumn 2, Issue 2, 2013, Pages 73-92

  Maguire, Jon ^a   Dhar, Vasant ^a  

^a NEW YORK UNIVERSITY   (United States)

Author keywords

claims data; comparative effectiveness; data mining; diabetes; healthcare; predictive analytics

Indexed keywords

EID: 84888421992     PISSN: 20476965     EISSN: 20476973     Source Type: Journal    
DOI: 10.1057/hs.2012.20     Document Type: Article

References (31)

1. Berger ML, Good research practices for comparative effectiveness research: defining, reporting and interpreting nonrandomized studies of treatment effects using secondary data sources: the ISPOR good research practices for retrospective database analysis task force report–part IValue in Health20091281062107310.1111/j.1524-4733.2009.00600.x
2. Bowker SL, Majumdar SR, Veugelers P, Johnson JA, Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulinDiabetes Care200629225425810.2337/diacare.29.02.06.dc05-1558
3. Breiman L, Friedman J, Olshen R and Stone C (1984) Classification and Regression Trees, Wadsworth International Group, Belmont, CA.
4. Centers for Disease Control (2010) Diabetes successes and opportunities for population-based prevention and control, at-a-glance 2010. Retrieved 27 December 2010 from [WWW document] http://www.cdc.gov/chronicdisease/resources/publications/aag/pdf/2010/diabetes_aag.pdf.
5. Congressional Budget Office (2007) The long-term outlook for health care spending, introduction and summary, November 2007. Retrieved 27 December 2010 from [WWW document] http://www.cbo.gov/ftpdocs/87xx/doc8758/MainText.3.1.shtml.
6. Department of Health and Human Services (2009a) Report to the president and the congress on comparative effectiveness research. Retrieved 27 December 2010 from [WWW document] http://www.hhs.gov/recovery/programs/cer/execsummary.html.
7. Department of Health and Human Services (2009b) Draft definition, prioritization criteria, and strategic framework [for CER] for public comment. Retrieved 27 December 2010 from [WWW document] http://www.hhs.gov/recovery/programs/cer/draftdefinition.html.
8. Department of Health and Human Services (2010) Department of health and human services agency-wide plan [for ARRA] (as of June 2010). Retrieved 27 December 2010 from [WWW document] http://www.hhs.gov/recovery/reports/plans/index.html.
9. Dhar V, Stein R, Seven Methods for Transforming Corporate Data into Business Intelligence1996
10. Eurich DT, Majumdar SR, McAlister FA, Tsuyuki RT, Johnson JA, Improved clinical outcomes associated with metformin in patients with diabetes and heart failureDiabetes Care200528102345235110.2337/diacare.28.10.2345
11. Eurich DT, Simpson SH, Majumdar SR, Johnson JA, Secondary failure rates associated with metformin and sulfonylurea therapy for type 2 diabetes mellitusPharmacotherapy200525681081610.1592/phco.2005.25.6.810
12. Hansen RA, Farley JF, Droege M, Maciejewski ML, A retrospective cohort study of economic outcomes and adherence to monotherapy with metformin, pioglitazone, or a sulfonylurea among patients with type 2 diabetes mellitus in the United States from 2003 to 2005Clinical Therapeutics20103271308131910.1016/j.clinthera.2010.07.011
13. Inzucchi SE, Management of hyperglycemia in type 2 diabetes: a patient-centered approachDiabetes Care20123561364137910.2337/dc12-0413
14. Johnson JA, Simpson SH, Toth EL, Majumdar SR, Reduced cardiovascular morbidity and mortality associated with metformin use in subjects with type 2 diabetesDiabetes Medicine200522449750210.1111/j.1464-5491.2005.01448.x
15. Kalsekar I, Latran M, Economic effect of augmentation strategies in patients with type 2 diabetes initiated on sulfonylureasManaged Care Interface20072093946
16. Karter AJ, Ahmed AT, Liu J, Moffet HH, Parker MM, Pioglitazone initiation and subsequent hospitalization for congestive heart failureDiabetes Medicine200522898699310.1111/j.1464-5491.2005.01704.x
17. National Institute of Diabetes and Digestive and Kidney Diseases (2011) National Diabetes Statistics, 2011. Retrieved 3 March 2011 from [WWW document] http://diabetes.niddk.nih.gov/DM/PUBS/statistics/.
18. Nichols GA, Koro CE, Gullion CM, Ephross SA, Brown JB, The incidence of congestive heart failure associated with antidiabetic therapiesDiabetes/Metabolism Research and Reviews2005211515710.1002/dmrr.480
19. Peirce CS, A theory of probable inferenceStudies in Logic by members of the Johns Hopkins University1883126181
20. Pople HE (1973) On the mechanization of abductive logic. Proceedings of the 3rd International Joint Conference on Artificial Intelligence, pp.147–152.
21. Pople HE (1977) The formation of composite hypotheses in diagnostic problem solving: an exercise in synthetic reasoning. Proceedings of the 5th International Joint Conference on Artificial Intelligence, pp.1030–1037.
22. SAS Institute. (2009) Enterprise miner product documentation. Retrieved 27 December 2010 from [WWW document] http://support.sas.com/documentation/onlinedoc/miner/.
23. Schneeweiss S, Developments in post-marketing comparative effectiveness researchClinical Pharmacology and Therapeutics200782214315610.1038/sj.clpt.6100249
24. Shortliffe EH, Buchanan BG, A model of inexact reasoning in medicineMathematical Biosciences1975233–435137910.1016/0025-5564(75)90047-4
25. Simpson SH, Majumdar SR, Tsuyuki RT, Eurich DT, Johnson JA, Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort studyCanadian Medical Association Journal2006174216917410.1503/cmaj.050748
26. Soni A, Top 10 most costly conditions among men and women, 2008: estimates for the U.S. civilian noninstitutionalized adult population, age 18 and olderAgency for Healthcare Research and Quality2011
27. Sullivan P, Goldmann D, The promise of comparative effectiveness researchJournal of the American Medical Association2011305440040110.1001/jama.2011.12
28. Szolovits P, Pauker SG, Categorical and probabilistic reasoning in medical diagnosisArtificial Intelligence19781111514410.1016/0004-3702(78)90014-0
29. Tzoulaki I, Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research databaseBritish Medical Journal2009339b473110.1136/bmj.b4731
30. U.S. Census Bureau. Census Regions and Divisions of the United States. Retrieved 5 November 2011 from [WWW document] http://www.census.gov/geo/www/us_regdiv.pdf.
31. U.S. Congress (2009) American recovery and reinvestment act of 2009. Retrieved 27 December 2010 from [WWW document] http://fdsys.gpo.gov/fdsys/pkg/BILLS-111hr1ENR/pdf/BILLS-111hr1ENR.pdf.